BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 22935382)

  • 21. Concurrent biological targeting therapy of squamous cell carcinoma of the esophagus with cetuximab and trastuzumab.
    Yamazaki M; Yamashita Y; Kubo N; Yashiro M; Ohira M; Ako E; Tanaka H; Muguruma K; Sawada T; Hirakawa K
    Oncol Rep; 2012 Jul; 28(1):49-54. PubMed ID: 22562413
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Potential therapeutic significance of HER-family in esophageal squamous cell carcinoma.
    Kono K; Mimura K; Fujii H; Shabbir A; Yong WP; Jimmy So A
    Ann Thorac Cardiovasc Surg; 2012; 18(6):506-13. PubMed ID: 23232268
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The relation of EGFR expression by immunohistochemical staining and clinical response of combination treatment of nimotuzumab and chemotherapy in esophageal squamous cell carcinoma.
    Jia J; Cui Y; Lu M; Wang X; Li J; Li J; Li Y; Zhang X; Gao J; Zhou J; Lu Z; Gong J; Yu J; Sun Z; Liu C; Shen L; Zhang X
    Clin Transl Oncol; 2016 Jun; 18(6):592-8. PubMed ID: 26459251
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Correlation of epidermal growth factor receptor overexpression with increased epidermal growth factor receptor gene copy number in esophageal squamous cell carcinomas.
    Yang YL; Xu KL; Zhou Y; Gao X; Chen LR
    Chin Med J (Engl); 2012 Feb; 125(3):450-4. PubMed ID: 22490401
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Patient-Derived Xenograft and Mice Models in Esophageal Squamous Cell Carcinoma.
    Lam AK; Tang JC
    Methods Mol Biol; 2020; 2129():137-147. PubMed ID: 32056175
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preclinical efficacy of Sym004, novel anti-EGFR antibody mixture, in esophageal squamous cell carcinoma cell lines.
    Fukuoka S; Kojima T; Koga Y; Yamauchi M; Komatsu M; Komatsuzaki R; Sasaki H; Yasunaga M; Matsumura Y; Doi T; Ohtsu A
    Oncotarget; 2017 Feb; 8(7):11020-11029. PubMed ID: 28038457
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cancer-associated fibroblasts mediated chemoresistance by a FOXO1/TGFβ1 signaling loop in esophageal squamous cell carcinoma.
    Zhang H; Xie C; Yue J; Jiang Z; Zhou R; Xie R; Wang Y; Wu S
    Mol Carcinog; 2017 Mar; 56(3):1150-1163. PubMed ID: 27769097
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nuclear Localization of DNAJB6 Is Associated With Survival of Patients With Esophageal Cancer and Reduces AKT Signaling and Proliferation of Cancer Cells.
    Yu VZ; Wong VC; Dai W; Ko JM; Lam AK; Chan KW; Samant RS; Lung HL; Shuen WH; Law S; Chan YP; Lee NP; Tong DK; Law TT; Lee VH; Lung ML
    Gastroenterology; 2015 Dec; 149(7):1825-1836.e5. PubMed ID: 26302489
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Afatinib against Esophageal or Head-and-Neck Squamous Cell Carcinoma: Significance of Activating Oncogenic HER4 Mutations in HNSCC.
    Nakamura Y; Togashi Y; Nakahara H; Tomida S; Banno E; Terashima M; Hayashi H; de Velasco MA; Sakai K; Fujita Y; Okegawa T; Nutahara K; Hamada S; Nishio K
    Mol Cancer Ther; 2016 Aug; 15(8):1988-97. PubMed ID: 27207775
    [TBL] [Abstract][Full Text] [Related]  

  • 30. eIF4E promotes tumorigenesis and modulates chemosensitivity to cisplatin in esophageal squamous cell carcinoma.
    Liu T; Li R; Zhao H; Deng J; Long Y; Shuai MT; Li Q; Gu H; Chen YQ; Leng AM
    Oncotarget; 2016 Oct; 7(41):66851-66864. PubMed ID: 27588477
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Patient-Derived Gastric Carcinoma Xenograft Mouse Models Faithfully Represent Human Tumor Molecular Diversity.
    Zhang T; Zhang L; Fan S; Zhang M; Fu H; Liu Y; Yin X; Chen H; Xie L; Zhang J; Gavine PR; Gu Y; Ni X; Su X
    PLoS One; 2015; 10(7):e0134493. PubMed ID: 26217940
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy.
    Arpino G; Gutierrez C; Weiss H; Rimawi M; Massarweh S; Bharwani L; De Placido S; Osborne CK; Schiff R
    J Natl Cancer Inst; 2007 May; 99(9):694-705. PubMed ID: 17470737
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of HER-2 status in breast carcinoma by fluorescence in situ hybridization and immunohistochemistry.
    Ogura H; Akiyama F; Kasumi F; Kazui T; Sakamoto G
    Breast Cancer; 2003; 10(3):234-40. PubMed ID: 12955036
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oncogenic alterations in ERBB2/HER2 represent potential therapeutic targets across tumors from diverse anatomic sites of origin.
    Chmielecki J; Ross JS; Wang K; Frampton GM; Palmer GA; Ali SM; Palma N; Morosini D; Miller VA; Yelensky R; Lipson D; Stephens PJ
    Oncologist; 2015 Jan; 20(1):7-12. PubMed ID: 25480824
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Comparison of B-NDG
    Guan L; Zou Q; Liu Q; Chen S
    Nan Fang Yi Ke Da Xue Xue Bao; 2020 Aug; 40(8):1200-1206. PubMed ID: 32895183
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of Smac in determining the chemotherapeutic response of esophageal squamous cell carcinoma.
    Xu Y; Zhou L; Huang J; Liu F; Yu J; Zhan Q; Zhang L; Zhao X
    Clin Cancer Res; 2011 Aug; 17(16):5412-22. PubMed ID: 21676925
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HER-2/neu status of primary breast cancer and corresponding metastatic sites in patients with advanced breast cancer treated with trastuzumab-based therapy.
    Pectasides D; Gaglia A; Arapantoni-Dadioti P; Bobota A; Valavanis C; Kostopoulou V; Mylonakis N; Karabelis A; Pectasides M; Economopoulos T
    Anticancer Res; 2006; 26(1B):647-53. PubMed ID: 16739334
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prospective antitumor effects of the combination of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and cisplatin against esophageal squamous cell carcinoma.
    Kondo K; Yamasaki S; Inoue N; Sugie T; Teratani N; Kan T; Shimada Y
    Surg Today; 2006; 36(11):966-74. PubMed ID: 17072716
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tumor xenograft animal models for esophageal squamous cell carcinoma.
    Lee NP; Chan CM; Tung LN; Wang HK; Law S
    J Biomed Sci; 2018 Aug; 25(1):66. PubMed ID: 30157855
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Patterns of her-2/neu amplification and overexpression in primary and metastatic breast cancer.
    Simon R; Nocito A; Hübscher T; Bucher C; Torhorst J; Schraml P; Bubendorf L; Mihatsch MM; Moch H; Wilber K; Schötzau A; Kononen J; Sauter G
    J Natl Cancer Inst; 2001 Aug; 93(15):1141-6. PubMed ID: 11481385
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.